The American Society of Clinical Oncology (ASCO) shared a post on X:
“ICYMI from ASCO24:
Although EAZ171 failed to meet its primary endpoint, Black patients with early-stage breast cancer who received docetaxel experienced less TIPN and fewer dose reductions than Black patients who received paclitaxel.”
Additional information.
Source: ASCO/X